Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Nab-paclitaxel for Second-line Advanced Gastric Cancer
NCT07320586Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Mar 2021
- Primary completion
- Jun 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab and paclitaxel in gastric cancer (GC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoints: Objective Response Rate up to 2 years and Median Progression-Free Survival at 2 years. Started Mar 2021; status: recruiting.
02
Drugs
camrelizumabpaclitaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT07320586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07320586.